Cargando…

Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System

BACKGROUND: The dopaminergic partial agonism of the so-called third-generation antipsychotics (TGAs; aripiprazole, brexpiprazole, cariprazine) is hypothesized to cause impulse control disorders (ICDs). Relevant warnings by the Food and Drug Administration (FDA) were posted on aripiprazole (2016) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Fusaroli, Michele, Raschi, Emanuel, Giunchi, Valentina, Menchetti, Marco, Rimondini Giorgini, Roberto, De Ponti, Fabrizio, Poluzzi, Elisabetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515127/
https://www.ncbi.nlm.nih.gov/pubmed/35639870
http://dx.doi.org/10.1093/ijnp/pyac031
_version_ 1784798423034101760
author Fusaroli, Michele
Raschi, Emanuel
Giunchi, Valentina
Menchetti, Marco
Rimondini Giorgini, Roberto
De Ponti, Fabrizio
Poluzzi, Elisabetta
author_facet Fusaroli, Michele
Raschi, Emanuel
Giunchi, Valentina
Menchetti, Marco
Rimondini Giorgini, Roberto
De Ponti, Fabrizio
Poluzzi, Elisabetta
author_sort Fusaroli, Michele
collection PubMed
description BACKGROUND: The dopaminergic partial agonism of the so-called third-generation antipsychotics (TGAs; aripiprazole, brexpiprazole, cariprazine) is hypothesized to cause impulse control disorders (ICDs). Relevant warnings by the Food and Drug Administration (FDA) were posted on aripiprazole (2016) and brexpiprazole (2018). Our study investigated the FDA Adverse Event Reporting System and the pharmacodynamic CHEMBL database to further characterize TGA-induced ICDs. METHODS: We downloaded and pre-processed the FDA Adverse Event Reporting System up to December 2020. We adapted Bradford Hill criteria to assess each TGA’s —and secondarily other antipsychotics’—causal role in inducing ICDs (pathological gambling, compulsive shopping, hyperphagia, hypersexuality), accounting for literature and disproportionality. ICD clinical features were analyzed, and their pathogenesis was investigated using receptor affinities. RESULTS: A total of 2708 reports of TGA-related ICDs were found, primarily recording aripiprazole (2545 reports, 94%) among the drugs, and gambling (2018 reports, 75%) among the events. Bradford-Hill criteria displayed evidence for a causal role of each TGA consistent across subpopulations and when correcting for biases. Significant disproportionalities also emerged for lurasidone with compulsive shopping, hyperphagia, and hypersexuality, and olanzapine and ziprasidone with hyperphagia. Time to onset varied between days and years, and positive dechallenge was observed in 20% of cases. Frequently, co-reported events were economic (50%), obsessive-compulsive (44%), and emotional conditions (34%). 5-Hydroxytryptamine receptor type 1a agonism emerged as an additional plausible pathogenetic mechanism. CONCLUSIONS: We detected an association between TGAs and ICDs and identified a new signal for lurasidone. ICD characteristics are behavior specific and may heavily impact on life. The role of 5-Hydroxytryptamine receptor type 1a agonism should be further explored.
format Online
Article
Text
id pubmed-9515127
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-95151272022-09-28 Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System Fusaroli, Michele Raschi, Emanuel Giunchi, Valentina Menchetti, Marco Rimondini Giorgini, Roberto De Ponti, Fabrizio Poluzzi, Elisabetta Int J Neuropsychopharmacol Regular Research Articles BACKGROUND: The dopaminergic partial agonism of the so-called third-generation antipsychotics (TGAs; aripiprazole, brexpiprazole, cariprazine) is hypothesized to cause impulse control disorders (ICDs). Relevant warnings by the Food and Drug Administration (FDA) were posted on aripiprazole (2016) and brexpiprazole (2018). Our study investigated the FDA Adverse Event Reporting System and the pharmacodynamic CHEMBL database to further characterize TGA-induced ICDs. METHODS: We downloaded and pre-processed the FDA Adverse Event Reporting System up to December 2020. We adapted Bradford Hill criteria to assess each TGA’s —and secondarily other antipsychotics’—causal role in inducing ICDs (pathological gambling, compulsive shopping, hyperphagia, hypersexuality), accounting for literature and disproportionality. ICD clinical features were analyzed, and their pathogenesis was investigated using receptor affinities. RESULTS: A total of 2708 reports of TGA-related ICDs were found, primarily recording aripiprazole (2545 reports, 94%) among the drugs, and gambling (2018 reports, 75%) among the events. Bradford-Hill criteria displayed evidence for a causal role of each TGA consistent across subpopulations and when correcting for biases. Significant disproportionalities also emerged for lurasidone with compulsive shopping, hyperphagia, and hypersexuality, and olanzapine and ziprasidone with hyperphagia. Time to onset varied between days and years, and positive dechallenge was observed in 20% of cases. Frequently, co-reported events were economic (50%), obsessive-compulsive (44%), and emotional conditions (34%). 5-Hydroxytryptamine receptor type 1a agonism emerged as an additional plausible pathogenetic mechanism. CONCLUSIONS: We detected an association between TGAs and ICDs and identified a new signal for lurasidone. ICD characteristics are behavior specific and may heavily impact on life. The role of 5-Hydroxytryptamine receptor type 1a agonism should be further explored. Oxford University Press 2022-05-27 /pmc/articles/PMC9515127/ /pubmed/35639870 http://dx.doi.org/10.1093/ijnp/pyac031 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of CINP. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Regular Research Articles
Fusaroli, Michele
Raschi, Emanuel
Giunchi, Valentina
Menchetti, Marco
Rimondini Giorgini, Roberto
De Ponti, Fabrizio
Poluzzi, Elisabetta
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System
title Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System
title_full Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System
title_fullStr Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System
title_full_unstemmed Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System
title_short Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System
title_sort impulse control disorders by dopamine partial agonists: a pharmacovigilance-pharmacodynamic assessment through the fda adverse event reporting system
topic Regular Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515127/
https://www.ncbi.nlm.nih.gov/pubmed/35639870
http://dx.doi.org/10.1093/ijnp/pyac031
work_keys_str_mv AT fusarolimichele impulsecontroldisordersbydopaminepartialagonistsapharmacovigilancepharmacodynamicassessmentthroughthefdaadverseeventreportingsystem
AT raschiemanuel impulsecontroldisordersbydopaminepartialagonistsapharmacovigilancepharmacodynamicassessmentthroughthefdaadverseeventreportingsystem
AT giunchivalentina impulsecontroldisordersbydopaminepartialagonistsapharmacovigilancepharmacodynamicassessmentthroughthefdaadverseeventreportingsystem
AT menchettimarco impulsecontroldisordersbydopaminepartialagonistsapharmacovigilancepharmacodynamicassessmentthroughthefdaadverseeventreportingsystem
AT rimondinigiorginiroberto impulsecontroldisordersbydopaminepartialagonistsapharmacovigilancepharmacodynamicassessmentthroughthefdaadverseeventreportingsystem
AT depontifabrizio impulsecontroldisordersbydopaminepartialagonistsapharmacovigilancepharmacodynamicassessmentthroughthefdaadverseeventreportingsystem
AT poluzzielisabetta impulsecontroldisordersbydopaminepartialagonistsapharmacovigilancepharmacodynamicassessmentthroughthefdaadverseeventreportingsystem